Navigation Links
Morphotek(R), Inc. and Eisai Corporation of North America Announce FDA Special Protocol Assessment (SPA) for Phase III Trial Evaluating Farletuzumab in Relapsed Ovarian Cancer
Date:3/23/2009

EXTON, Pa., March 23 /PRNewswire/ -- Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced today that the U.S. Food and Drug Administration (FDA) has agreed to and approved the design of a single, pivotal, Phase III clinical trial evaluating farletuzumab (also known as MORAb-003) in platinum-sensitive ovarian cancer patients experiencing their first relapse. The agreement was made under the Special Protocol Assessment (SPA) procedure.

"We are pleased that the FDA has approved the protocol for this Phase III study of farletuzumab in first-relapsed, platinum-sensitive ovarian cancer," stated Martin D. Phillips, M.D., Chief Medical Officer of Morphotek. "Physicians and patients do not have many good choices for treating ovarian cancer at this stage, and we are hopeful that some day farletuzumab may provide an option for ovarian cancer patients and their caregivers."

Morphotek is currently concluding a Phase II trial with farletuzumab as a single-agent and in combination with standard-of-care chemotherapy (carboplatin and taxane) in platinum-sensitive ovarian cancer patients experiencing a first relapse of their disease. The trial was designed to measure objective rate of response, and to compare the length of a patient's second remission with her first remission. Interim results from the study demonstrated an encouraging rate of durable objective response in patients on combination therapy. These findings prompted pursuit of a definitive pivotal study to evaluate the capacity of farletuzumab to benefit patients with ovarian cancer in a rigorously controlled manner.

The Phase III study, the design of which was agreed to by FDA, will assess the capacity of farletuzumab to extend progression free survival and overall survival in combination with carboplatin and taxane at two different dose levels of farletuzumab. The study will be conducted as a randomized, double-blind, plac
'/>"/>

SOURCE Morphotek, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Eisai Corporation of North America Announces Appointment of Vice President of U.S. Corporate Communications
2. Eisai Inc. and the Alzheimers Association Introduce the C.A.R.E. Pharmacy Award and Call for Nominations
3. Eisai Renews Its Commitment to Responsible Healthcare Community Interactions in Accordance with the Revised PhRMA Marketing Code
4. Eisai Inc. Supports Acting Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
5. Biologic Drugs, Particularly Centocor/Janssen-Cilags Stelara and Abbott/Eisais Humira, will Drive the Psoriasis Drug Market to $5 Billion by 2017
6. Eisai Will Initiate First Head-to-Head Study Comparing Dacogen(R) (decitabine for injection) and Vidaza(R) (azacitidine) in Patients with Myelodysplastic Syndromes
7. Eisai Inc. and the North American Thrombosis Forum (NATF)* Introduce the DVTeamCare(TM) Hospital Award and Call for Nominations
8. Eisai and Bial Announce Partnership Agreement for the European Commercialisation of the Novel Once Daily Anti-Epileptic Zebinix(R)
9. Teikoku Pharma USA and Eisai Co., Ltd. Announce Licensing Agreement for a New 7-Day Transdermal Formulation of Donepezil.
10. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
11. Brooke Franchise Corporation Announces Selected July Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... ... ... The Lisle family law firm of Momkus McCluskey, LLC is pleased ... earn a “Leading Lawyers” distinction. , The “Leading Lawyers” distinction is ... nomination process is based on statewide peer survey nominations and the approval of the ...
(Date:8/31/2015)... ... 31, 2015 , ... Patients who thought about getting a hair transplant but ... more about the procedure beyond the information found on the Internet can attend the ... Parsa Mohebi will be on hand to answer patients hair transplant questions at ...
(Date:8/31/2015)... ... September 01, 2015 , ... ... for traumatic brain injury with emphasis on transcranial near-infrared laser phototherapy ”. , ... Traumatic brain injury has been largely untreatable - with mostly palliative treatments only ...
(Date:8/31/2015)... ... August 31, 2015 , ... Dr. Paul Kovatis of Orthopedic Spine & Sports ... Dr. Kovatis treats all surgical and non-surgical disorders of the leg, ankle and foot. ... system, excluding the spine. , Dr. Paul Kovatis completed his orthopedic leg, ankle and ...
(Date:8/31/2015)... , ... August 31, 2015 , ... ... digital marketing communications company announced today that it has officially launched a new ... the new website and brand refresh are more closely aligned with the company’s ...
Breaking Medicine News(10 mins):Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:Watch a Live Hair Transplant at Parsa Mohebi Hair Restoration’s Open House 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 2Health News:Near-Infrared Laser Phototherapy for Brain Injury published by Dove Medical Press 3Health News:NJ Top Docs Presents, Dr. Paul Kovatis of Orthopedic Spine & Sports Medicine Center on his Five Year Anniversary as an "NJ Top Doc" 2Health News:Diablo Publications Launches New Company Website 2Health News:Diablo Publications Launches New Company Website 3
... , , , CHARLES TOWN, ... a provider of electronic treatments for the pain resulting from peripheral ... released a new way to deliver the impulses of the ReBuilder ... , , Physicians all over the U.S. are ...
... , WASHINGTON, Sept. 2 Hollywood ... Murtaugh in the blockbuster Lethal Weapon movies, will be ... a 30-minute public affairs television program that tells the compelling and ... Sunday morning on more than 300 television stations nationwide. , ...
... Medical School,s Strelitz Diabetes Center have been awarded a ... Foundation (JDRF). The center,s research team, led by ... and director of the center, has been studying the ... damaging insulin-producing beta cells, a condition that leads to ...
... , HARRISBURG, Pa., Sept. 2 United Concordia Dental ... resin fillings -- for its Concordia Flex((R)), Concordia Preferred((R)) and Concordia ... , , "Brokers, employers and members asked ... said Sharon Muscarella, United Concordia senior vice president of sales and ...
... , , BATESVILLE, Ind., ... Radianse today announced a strategic partnership agreement to integrate the ... Call system. With this move, Hill-Rom intends to extend ... remove financial and technical obstacles for health care customers as ...
... VIENNA, Va., Sept. 2 CEL-SCI Corporation ... the prevention and treatment of infectious diseases and a late-stage oncology ... "Notes"). The Notes, which had an initial principal value of ... common stock. , , "The elimination of the ...
Cached Medicine News:Health News:ReBuilder Medical Technologies, Inc. Announces Unique Arthritic Pain Accessory 2Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 2Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 3Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 4Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 5Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 6Health News:'Sharing Miracles' Television Program to Feature Award-Winning Hollywood Star Danny Glover 7Health News:JDRF award supports study of potential target for blocking type 1 diabetes 2Health News:United Concordia Dental Expands Benefit Options 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 2Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 3Health News:Hill-Rom and Radianse Announce Partnering Agreement to Integrate Location-Sensing Technology into NaviCare(R) Nurse Call 4Health News:CEL-SCI Corporation Announces Elimination of $8.3 Million Convertible Notes 2
(Date:8/31/2015)... , Aug. 31, 2015 Research and ... of the "Prescription Pain Drugs - Including ... - Global Markets, Competitors and Opportunities: 2015 - ... offering. Pain is defined as ... actual or potential tissue damage. At some point, ...
(Date:8/29/2015)... 29, 2015 La sofisticada ... los sistemas de imagen por Ultrasonidos   ofrece resultados ... examen rápidos y un flujo de trabajo   optimizado, ... el proceso de detección de Cardiopatías   ... hoy el lanzamiento europeo de HeartModel A.I ...
(Date:8/28/2015)... SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2015 ... therapeutics for the treatment of cancer, today announced the ... the U.S. Securities and Exchange Commission (SEC) relating to ... The number of shares to be offered and the ... determined. CytomX intends to list its common stock under ...
Breaking Medicine Technology:Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3Philips presenta HeartModel A.I en el Congreso ESC 2015 2Philips presenta HeartModel A.I en el Congreso ESC 2015 3Philips presenta HeartModel A.I en el Congreso ESC 2015 4Philips presenta HeartModel A.I en el Congreso ESC 2015 5CytomX Files Registration Statement for Proposed Initial Public Offering 2
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
... only catheter of its kind, the ... collects real-time cardiac electrical information, translating ... With 64 electrodes, this unique tool ... than 3,000 points of electrical data ...
... The St. Jude Medical® Pacing System Analyzer ... solution for implantation testing, programming and interrogation ... as an easy-to-use accessory to the St. ... testing by obtaining measurements of intrinsic P- ...
Medicine Products: